EUCTR2015-004566-28-FR进行中（未招募）1 期
A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224) - Phase II MK-3475 in subjects with previously treated Hepatocellular Carcinoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Subjects must: provide informed consent, be > or = 18 years of age, have confirmed diagnosis of HCC, have a life expectancy greater than 3 months, have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach, have a Child-Pugh A liver score, have measurable disease based on RECIST 1.1 as confirmed by central imaging vendor, have ECOG Performance Scale of 0 or 1, have documented objective radiographic progression after stopping treatment with sorafenib or else intolerance to sorafenib, be untreated for chronic HCV or 4 weeks have passed between completion of HCV therapy and start of study drug, demonstrate adequate organ function, have negative pregnancy test for females of child bearing potential prior to starting study and male and female subjects of childbearing potential must be willing to use an adequate method of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •The subject will be excluded from participating in the trial if the subject: is currently participating and receiving study therapy or has participated in an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigational device within 4 weeks of the first dose of treatment, has received sorafenib within 14 days of first dose of study medication, has had esophageal or gastric variceal bleeding within the last 6 months, has clinically apparent ascites on physical examination, ascites detectable on imaging studies only IS allowed), has portal vein invasion of HCC based on imaging, has had encephalopathy in the last 6 months, had a solid organ or hematologic transplant, had prior systemic therapy for HCC other than sorafenib, or intercurrent local therapy to the liver tumor between sorafenib and study drug, has active autoimmune disease that required treatment in the past two years, has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, has received locoregional therapy to liver or major surgery to liver or other site within 6 weeks prior to the first dose of study drug, has a diagnosed additional malignancy within 5 years prior to first dose of trial treatment with some exceptions, has radiographically detectable central nervous system (CNS) metastases and/or carcinomatous meningitis, has a known history of, or evidence of, interstitial lung disease or active non-infectious pneumonitis, has an active infection requiring systemic therapy, has known psychiatric or substance abuse disorders, is pregnant or breastfeeding, has received prior immunotherapy or previously participated in Merck pembrolizumab clinical trials, has untreated active Hepatitis B, has dual infection with HBV/HCV or other hepatitis combinations at study entry, has received a live vaccine within 30 days of planned start of study therapy, with exception for killed virus vaccines used for seasonal influenza vaccines.
研究者
相似试验
进行中（未招募）
1 期
A Phase II Study of Pembrolizumab in Previously Treated Subjects with Mismatched Repair Deficient or Microsatellite Instability-High Colorectal CarcinomaEUCTR2015-001852-32-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.60
进行中（未招募）
1 期
A Phase II Study of Pembrolizumab in Previously Treated Subjects with Mismatched Repair Deficient or Microsatellite Instability-High Colorectal CarcinomaEUCTR2015-001852-32-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.120
进行中（未招募）
1 期
A Phase II Study of Pembrolizumab in Previously Treated Subjects with Mismatched Repair Deficient or Microsatellite Instability-High Colorectal CarcinomaColorectal CarcinomaEUCTR2015-001852-32-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.120
进行中（未招募）
1 期
A Phase II Study of Pembrolizumab in Previously Treated Subjects with Mismatched Repair Deficient or Microsatellite Instability-High Colorectal CarcinomaEUCTR2015-001852-32-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.60
进行中（未招募）
1 期
A Phase 2 Study of Pembrolizumab (MK-3475) in subjects with Advanced Hepatocellular CarcinomaMedDRA version: 21.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular CarcinomaEUCTR2015-004566-28-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.150